Skip to main content
. 2021 Jun 8;11:642134. doi: 10.3389/fonc.2021.642134

Figure 5.

Figure 5

NHWD-870 inhibited the growth of osteosarcoma in vivo. (A) Gross tumor specimens in each group. (B) The daily change in tumor volume in each group and NHWD-870 showed dose-dependent inhibition of tumor growth in vivo. (****P < 0.0001). (C) Tumor weight of gross tumor specimens in each group at day 21, further demonstrating that NHWD-870 inhibited tumor growth. (****P < 0.0001). (D) Changes in the protein expression of PCNA, GP130 and activation of STAT3 signaling pathways were detected in tumor tissue in each group by western blotting. (E) Changes in the protein expression of PCNA, GP130 and activation of STAT3 signaling pathways in tumor tissues in each group were detected by immunohistochemistry, and TUNEL staining showed that NHWD-870 could significantly induce apoptosis in tumor tissues. Scale bar = 100 μm. (F) The systemic toxicity of NHWD-870 to vital organs in vivo was evaluated by H&E staining. Scale bar = 400 μm. (****, P < 0.0001).